Need help now? Free crisis lines and helplines, worldwide — chapter 02 →
0 results for

Metabolic Health — Low-Carb, Ketogenic & Remission Diets for Diabetes, Weight & Insulin Resistance

Category 1 of 20 in chapter 17, The Research Behind It, of Notbroken's Free Metabolic & Mental Health Help Directory: 13 listings, each carefully picked (listed, not endorsed). All 280 listings in The Research Behind It · Open the full directory of 2299 listings.
13
Listings
1 / 20
Category
17 / 18
Chapter
Latest Edition Always download the most up-to-date version, free, at notbroken.io
Know someone who could benefit? Share this guide with them.
Free to use · No account needed
Navigation
Contents
17
The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows
THE EVIDENCE
THE EVIDENCE

The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows

Why would a support group, a walking club, a low-carb book or an online CBT course help — and what drives chronic illness in the first place? This chapter gathers the research behind each part of the directory, and the research on causes: metabolic therapies, the nutrients in food, plastics and pollution, stress and trauma, the microbiome, and damp and mould. That is 280 studies, reviews and clinical guidelines, every one free to read and download in full, permanently and without a login. Most are kept in PubMed Central, the US National Library of Medicine's public archive; the rest are open access at the publisher, or free guidance from the World Health Organization and NICE. Each entry says what was found, why it matters here — which listings it backs up, or what it explains about chronic disease — and how strong the evidence is: strong (systematic reviews and guidelines with consistent findings), moderate (smaller or lower-certainty reviews, single large trials and large cohort studies) or early (pilot, cross-sectional and laboratory studies — promising, not proof). Studies that follow people over time show links, not proof of cause, and the entries say so. Where a study was funded by a company, or its authors run a listed programme, the note says so; where a listed book or service was not itself tested, the entry says it backs the approach rather than the product. Research moves on, so read these as good reasons to try something, not guarantees — and talk to your own clinician before changing a treatment or a medicine. Every paper was checked at least twice: by the researcher who chose it and again, independently, against its abstract and full text (the first 186 a third time); its public record was checked for corrections, retractions and expressions of concern (none is retracted), every number was looked up in the full text, and every link was opened in a browser.

Metabolic Health — Low-Carb, Ketogenic & Remission Diets for Diabetes, Weight & Insulin Resistance

Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission — Churuangsuk et al., Diabetologia 2022

Umbrella review of 21 systematic reviews (19 meta-analyses) of randomised trials, plus a systematic review of 14 remission studies. Strong evidence. Diabetologia 2022;65(1):14–36. DOI 10.1007/s00125-021-05577-2. Free full text in PubMed Central (PMC8660762) — open access, CC BY 4.0. Note: Most of the evidence covers 1 year or less; it does not show low-carb beats other diets for weight, and remission evidence for ketogenic diets is very low certainty.
What It Found
Brought together 19 published meta-analyses of weight-loss diets for type 2 diabetes. Low-carbohydrate diets were no better for weight loss than higher-carbohydrate, low-fat diets (high certainty), and no nutrient mix came out ahead, though very-low-energy and formula meal-replacement diets gave the most weight loss. Programmes starting with formula total diet replacement gave the highest 1-year remission: a median 54%, against 4–12% with usual care (high certainty).
Why It Matters Here
Backs up Roy Taylor's Life Without Diabetes (chapter 10), whose plan starts with a formula low-calorie phase, and the low-carb guides in chapter 10 and low-carb clinicians in chapter 01 as one option among several: no single diet style wins for weight.
Umbrella review of 21 systematic reviews (19 meta-analyses) of randomised trials, plus a systematic review of 14 remission studies. Strong evidence. Diabetologia 2022;65(1):14–36. DOI 10.1007/s00125-021-05577-2. Free full text in PubMed Central (PMC8660762) — open access, CC BY 4.0. Note: Most of the evidence covers 1 year or less; it does not show low-carb beats other diets for weight, and remission evidence for ketogenic diets is very low certainty.

Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data — Goldenberg et al., BMJ 2021

Systematic review and meta-analysis — 23 randomised trials, 1,357 adults with type 2 diabetes. Moderate evidence. BMJ 2021;372:m4743. DOI 10.1136/bmj.m4743. Free full text in PubMed Central (PMC7804828) — open access, CC BY-NC 4.0. Note: Remission here allowed diabetes medicines; counting only people off medication, the benefit was small and uncertain (low certainty). Remission data at 12 months were sparse.
What It Found
Pooled 23 randomised trials of low-carbohydrate diets (under 130 g a day) lasting at least 12 weeks. At 6 months, 57% on low-carb diets reached remission (HbA1c below 6.5%) versus 31% on control diets (risk difference 32%, moderate certainty), with more weight loss and better triglycerides and insulin sensitivity. Most of these benefits shrank by 12 months, and no clear increase in adverse events was seen.
Why It Matters Here
Backs up the low-carb approach of the practitioner directories in chapter 01, the LCHF and keto communities in chapters 13 and 14, and the guides in chapter 10 (Diet Doctor, Freshwell, Phinney & Volek, Westman), mainly for adults with type 2 diabetes.
Systematic review and meta-analysis — 23 randomised trials, 1,357 adults with type 2 diabetes. Moderate evidence. BMJ 2021;372:m4743. DOI 10.1136/bmj.m4743. Free full text in PubMed Central (PMC7804828) — open access, CC BY-NC 4.0. Note: Remission here allowed diabetes medicines; counting only people off medication, the benefit was small and uncertain (low certainty). Remission data at 12 months were sparse.

5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study — Lean et al., Lancet Diabetes Endocrinol 2024

Extension study of a cluster-randomised trial (DiRECT, 49 UK general practices) — 5-year follow-up. Moderate evidence. Lancet Diabetes Endocrinol 2024;12(4):233–246. Free full text at the publisher — open access, CC BY 4.0. Note: Only 95 of 149 intervention participants joined the non-randomised extension, and remission fell over time as average weight loss shrank; lasting remission needs weight kept off.
What It Found
DiRECT tested a GP-practice programme of low-calorie formula diet (total diet replacement), food reintroduction and ongoing support. At 2 years, 36% of the intervention group were in remission (mean loss 7.6 kg). Of 95 who took up 3 more years of light support, 85 were seen at 5 years: 13% were in remission (mean loss 6.1 kg), and 26% of those in remission at 2 years still were. Over 5 years the intervention group was in remission at 27% of visits, controls at 4%.
Why It Matters Here
Backs up Roy Taylor's Life Without Diabetes (chapter 10), which sets out the DiRECT/Newcastle plan, and GP-supported remission programmes, while showing that keeping weight off long term is the hard part.
Extension study of a cluster-randomised trial (DiRECT, 49 UK general practices) — 5-year follow-up. Moderate evidence. Lancet Diabetes Endocrinol 2024;12(4):233–246. Free full text at the publisher — open access, CC BY 4.0. Note: Only 95 of 149 intervention participants joined the non-randomised extension, and remission fell over time as average weight loss shrank; lasting remission needs weight kept off.

Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials — Ge et al., BMJ 2020

Systematic review and network meta-analysis — 121 randomised trials, 21,942 adults with overweight or obesity. Strong evidence. BMJ 2020;369:m696. DOI 10.1136/bmj.m696. Free full text in PubMed Central (PMC7190064) — open access, CC BY-NC 4.0. Note: Differences between diets were small, and benefits of every diet, low-carb included, largely faded by 12 months.
What It Found
Compared 14 named diets, including Atkins and other low-carbohydrate plans, and broad diet types. At 6 months, low-carbohydrate and low-fat diets cut weight by 4.63 kg and 4.40 kg more than usual diet (moderate certainty; low-fat figure from a 2020 correction), with similar falls in blood pressure; Atkins gave about 5.5 kg. By 12 months weight loss had shrunk for every diet, and improvements in heart-risk factors had largely gone, except with the Mediterranean diet.
Why It Matters Here
Backs up the low-carb approach taught by the books, guides and apps in chapters 10 and 16 and followed in the LCHF and keto communities in chapters 13 and 14, as one reasonable choice among several for weight loss rather than a superior one.
Systematic review and network meta-analysis — 121 randomised trials, 21,942 adults with overweight or obesity. Strong evidence. BMJ 2020;369:m696. DOI 10.1136/bmj.m696. Free full text in PubMed Central (PMC7190064) — open access, CC BY-NC 4.0. Note: Differences between diets were small, and benefits of every diet, low-carb included, largely faded by 12 months.

Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials — Semnani-Azad et al., BMJ 2025

Systematic review and network meta-analysis — 99 randomised trials, 6,582 adults. Strong evidence. BMJ 2025;389:e082007. DOI 10.1136/bmj-2024-082007. Free full text in PubMed Central (PMC12175170) — open access, CC BY-NC 4.0. Note: Most trials were short (median 12 weeks); in trials of 24 weeks or more, fasting was no better than ordinary calorie cutting.
What It Found
Compared alternate-day fasting, time-restricted eating and whole-day fasting (such as 5:2) with everyday calorie cutting and with no diet. Every fasting approach and continuous calorie restriction reduced weight compared with no diet. Alternate-day fasting gave slightly more loss than continuous restriction (1.29 kg, moderate certainty); otherwise fasting and calorie cutting had similar effects on weight and cardiometabolic risk factors.
Why It Matters Here
Backs up the intermittent fasting approach in Jason Fung's books (chapter 10), The Fasting Method community, the Zero app and Mayo Clinic's LCHF and fasting group (chapter 13): fasting is a workable way to eat less, not a superior one.
Systematic review and network meta-analysis — 99 randomised trials, 6,582 adults. Strong evidence. BMJ 2025;389:e082007. DOI 10.1136/bmj-2024-082007. Free full text in PubMed Central (PMC12175170) — open access, CC BY-NC 4.0. Note: Most trials were short (median 12 weeks); in trials of 24 weeks or more, fasting was no better than ordinary calorie cutting.

Nutrition therapy for adults with diabetes or prediabetes: a consensus report — Evert et al., Diabetes Care 2019

Consensus report of the American Diabetes Association: expert recommendations based on a PubMed review of studies published 2014–2018. Strong evidence. Diabetes Care 2019;42(5):731–754. DOI 10.2337/dci19-0014. Free full text in PubMed Central (PMC7011201). Note: Very-low-carb plans can lower blood glucose quickly, so insulin and similar medicines may need reducing from the start; more research is needed in pregnancy, kidney disease and disordered eating.
What It Found
The American Diabetes Association's guidance on eating for diabetes and prediabetes. It concludes that reducing overall carbohydrate intake has the most evidence for improving blood glucose, and that low- or very-low-carbohydrate eating plans are a viable approach for selected adults with type 2 diabetes not meeting targets or wanting to reduce medicines. It also says no single eating pattern is best for everyone and that remission rises with the amount of weight lost.
Why It Matters Here
Backs up the clinician-supported low-carb care in chapter 01 and the low-carb approach of the programmes and guides in chapters 10 and 16, and gives readers a mainstream statement to take to their own doctor or dietitian.
Consensus report of the American Diabetes Association: expert recommendations based on a PubMed review of studies published 2014–2018. Strong evidence. Diabetes Care 2019;42(5):731–754. DOI 10.2337/dci19-0014. Free full text in PubMed Central (PMC7011201). Note: Very-low-carb plans can lower blood glucose quickly, so insulin and similar medicines may need reducing from the start; more research is needed in pregnancy, kidney disease and disordered eating.

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin — Knowler et al., N Engl J Med 2002

Randomised controlled trial — 3,234 adults with raised blood glucose, average follow-up 2.8 years. Moderate evidence. N Engl J Med 2002;346(6):393–403. DOI 10.1056/NEJMoa012512. Free full text in PubMed Central (PMC1370926). Note: The lifestyle programme was intensive and not a low-carb diet; later follow-up found the prevention effect narrowed over time.
What It Found
The landmark US Diabetes Prevention Program randomised adults with prediabetes to an intensive lifestyle programme (goals: 7% weight loss and 150 minutes of activity a week), metformin or placebo. The lifestyle programme cut new cases of type 2 diabetes by 58% (95% CI 48–66%) compared with placebo, and metformin by 31%; about 7 people needed the lifestyle programme for 3 years to prevent one case.
Why It Matters Here
Backs up the CDC National Diabetes Prevention Program in chapter 16, which is built on this trial, and lifestyle support for anyone told they have prediabetes.
Randomised controlled trial — 3,234 adults with raised blood glucose, average follow-up 2.8 years. Moderate evidence. N Engl J Med 2002;346(6):393–403. DOI 10.1056/NEJMoa012512. Free full text in PubMed Central (PMC1370926). Note: The lifestyle programme was intensive and not a low-carb diet; later follow-up found the prevention effect narrowed over time.

Effects of a low-carbohydrate dietary intervention on hemoglobin A1c: a randomized clinical trial — Dorans et al., JAMA Netw Open 2022

Randomised controlled trial — 150 adults with untreated HbA1c 6.0–6.9%, 6 months. Moderate evidence. JAMA Netw Open 2022;5(10):e2238645. DOI 10.1001/jamanetworkopen.2022.38645. Free full text in PubMed Central (PMC9606840) — open access, CC BY 4.0. Note: A single 6-month trial; the authors could not separate the effect of carbohydrate cutting from weight loss, and long-term results are unknown.
What It Found
Adults with raised blood glucose (HbA1c 6.0–6.9%, prediabetes or early untreated diabetes) not taking diabetes medicines were randomised to a low-carbohydrate diet (under 40 g net carbohydrate a day for 3 months, then under 60 g) or their usual diet. After 6 months the low-carb group's HbA1c was 0.23 percentage points lower, fasting glucose 10.3 mg/dL lower and weight 5.9 kg lower than the usual-diet group.
Why It Matters Here
Backs up low-carb eating for people with raised blood glucose not yet on diabetes medicines — the approach in the low-carb guides and Ben Bikman's book in chapter 10 and used by the low-carb practitioners in chapter 01.
Randomised controlled trial — 150 adults with untreated HbA1c 6.0–6.9%, 6 months. Moderate evidence. JAMA Netw Open 2022;5(10):e2238645. DOI 10.1001/jamanetworkopen.2022.38645. Free full text in PubMed Central (PMC9606840) — open access, CC BY 4.0. Note: A single 6-month trial; the authors could not separate the effect of carbohydrate cutting from weight loss, and long-term results are unknown.

Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial — Holmer et al., JHEP Rep 2021

Randomised controlled trial — 74 adults with non-alcoholic fatty liver disease, 12 weeks. Moderate evidence. JHEP Rep 2021;3(3):100256. DOI 10.1016/j.jhepr.2021.100256. Free full text in PubMed Central (PMC8059083) — open access, CC BY 4.0. Note: A small 12-week trial; 20% dropped out of the LCHF arm (mainly stomach upsets), and long-term liver outcomes are unknown.
What It Found
People with fatty liver were randomised to a low-carbohydrate high-fat (LCHF) diet, the 5:2 intermittent fasting diet or standard advice from a liver specialist. Liver fat fell by 7.2 percentage points with LCHF and 6.1 with 5:2, versus 3.6 with standard care, and weight by 7.3 kg and 7.4 kg versus 2.5 kg. The two diets worked about equally well; 5:2 was better tolerated and was linked to lower LDL cholesterol.
Why It Matters Here
Backs up the fatty-liver focus of Ben Bikman's and Jason Fung's books (chapter 10), low-carb clinicians in chapter 01 and the LCHF and fasting groups in chapter 13: either approach can reduce liver fat.
Randomised controlled trial — 74 adults with non-alcoholic fatty liver disease, 12 weeks. Moderate evidence. JHEP Rep 2021;3(3):100256. DOI 10.1016/j.jhepr.2021.100256. Free full text in PubMed Central (PMC8059083) — open access, CC BY 4.0. Note: A small 12-week trial; 20% dropped out of the LCHF arm (mainly stomach upsets), and long-term liver outcomes are unknown.

Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake — Hall et al., Cell Metab 2019

Randomised crossover trial — 20 adults living on a research ward, 2 weeks on each diet. Moderate evidence. Cell Metab 2019;30(1):67–77.e3. DOI 10.1016/j.cmet.2019.05.008. Free full text in PubMed Central (PMC7946062). Note: Only 20 people for 4 weeks on a research ward; it shows short-term overeating, not long-term weight or disease outcomes.
What It Found
A tightly controlled US National Institutes of Health trial in which 20 adults ate an ultra-processed or an unprocessed diet for two weeks each, in random order, eating as much as they wanted. On the ultra-processed diet they ate about 508 kcal more per day and gained about 0.9 kg; on the unprocessed diet they lost about 0.9 kg.
Why It Matters Here
Backs up the books on ultra-processed food in chapter 10 — Chris van Tulleken's Ultra-Processed People and Robert Lustig's Metabolical — and the real-food cooking resources in chapter 14.
Randomised crossover trial — 20 adults living on a research ward, 2 weeks on each diet. Moderate evidence. Cell Metab 2019;30(1):67–77.e3. DOI 10.1016/j.cmet.2019.05.008. Free full text in PubMed Central (PMC7946062). Note: Only 20 people for 4 weeks on a research ward; it shows short-term overeating, not long-term weight or disease outcomes.

Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: a 2-year non-randomized clinical trial — Athinarayanan et al., Front Endocrinol 2019

Non-randomised controlled trial — 262 adults on the intervention, 87 on usual care, 2 years. Early evidence. Front Endocrinol 2019;10:348. DOI 10.3389/fendo.2019.00348. Free full text in PubMed Central (PMC6561315) — open access, CC BY 4.0. Note: Not randomised (people chose their group), run and mostly written by the company, and about a quarter of participants lacked 2-year data.
What It Found
Adults with type 2 diabetes chose remote, app-based coaching with doctor-supervised nutritional ketosis (Virta Health) or usual care. After 2 years the ketosis group's HbA1c had fallen 12% (from 7.7%) and weight 10%; use of diabetes medicines other than metformin fell from 55.7% to 26.8%, insulin use by 62% and sulfonylurea use stopped entirely. 53.5% met the study's definition of diabetes 'reversal' and 17.6% 'remission'; usual care showed no such changes.
Why It Matters Here
Backs up clinician-supervised ketogenic care for type 2 diabetes — the low-carb doctors and coaches in chapter 01 and Dr Sarah Hallberg's talk and Dr Eric Westman's courses in chapter 10 — especially where medicines need adjusting.
Non-randomised controlled trial — 262 adults on the intervention, 87 on usual care, 2 years. Early evidence. Front Endocrinol 2019;10:348. DOI 10.3389/fendo.2019.00348. Free full text in PubMed Central (PMC6561315) — open access, CC BY 4.0. Note: Not randomised (people chose their group), run and mostly written by the company, and about a quarter of participants lacked 2-year data.

What predicts drug-free type 2 diabetes remission? Insights from an 8-year general practice service evaluation of a lower carbohydrate diet with weight loss — Unwin et al., BMJ Nutr Prev Health 2023

Service evaluation (uncontrolled cohort) — 186 people with type 2 diabetes in one UK general practice, 2013–2021. Early evidence. BMJ Nutr Prev Health 2023;6(1):46–55. DOI 10.1136/bmjnph-2022-000544. Free full text in PubMed Central (PMC10407412) — open access, CC BY-NC 4.0. Note: An uncontrolled audit of volunteers in one practice, with no comparison group; results may not apply to everyone offered the diet.
What It Found
A UK GP practice offered a lower-carbohydrate diet to people with type 2 diabetes; 186 took it up and were followed for an average of 33 months. Median weight fell from 97 to 86 kg and HbA1c from 63 to 46 mmol/mol, and 51% achieved drug-free remission — 77% of those diagnosed under a year earlier but 20% of those diagnosed over 15 years. LDL cholesterol, triglycerides and blood pressure also fell, and the practice spent less on diabetes drugs.
Why It Matters Here
Backs up GP-led low-carb care — the approach behind Dr David Unwin's sugar infographics (Public Health Collaboration) and the similar Freshwell project in chapter 10, and used by low-carb practitioners in chapter 01 — especially soon after diagnosis.
Service evaluation (uncontrolled cohort) — 186 people with type 2 diabetes in one UK general practice, 2013–2021. Early evidence. BMJ Nutr Prev Health 2023;6(1):46–55. DOI 10.1136/bmjnph-2022-000544. Free full text in PubMed Central (PMC10407412) — open access, CC BY-NC 4.0. Note: An uncontrolled audit of volunteers in one practice, with no comparison group; results may not apply to everyone offered the diet.

Effects of ketogenic diet on reproductive hormones in women with polycystic ovary syndrome — Khalid et al., J Endocr Soc 2023

Systematic review and meta-analysis — 7 small clinical trials (4 single-arm), 170 women. Early evidence. J Endocr Soc 2023;7(10):bvad112. DOI 10.1210/jendso/bvad112. Free full text in PubMed Central (PMC10484165) — open access, CC BY-NC-ND 4.0. Note: Few, small and mostly uncontrolled studies; the authors say results must be interpreted carefully. PCOS guidelines do not yet favour any one diet.
What It Found
Combined 7 small trials of ketogenic diets lasting 45 days to 24 weeks in women with polycystic ovary syndrome (PCOS). Pooled results suggested a lower LH/FSH ratio and lower free testosterone, higher sex-hormone-binding globulin, and weight loss in every study — changes in the hormone pattern behind many PCOS symptoms. The authors describe a possible link that needs confirming.
Why It Matters Here
Backs up the PCOS advice in Ben Bikman's Why We Get Sick (chapter 10) and low-carb clinicians in chapter 01, as an early option for women with PCOS to discuss with their doctor; most relevant to women with PCOS, including members of PCOS Challenge (chapter 06).
Systematic review and meta-analysis — 7 small clinical trials (4 single-arm), 170 women. Early evidence. J Endocr Soc 2023;7(10):bvad112. DOI 10.1210/jendso/bvad112. Free full text in PubMed Central (PMC10484165) — open access, CC BY-NC-ND 4.0. Note: Few, small and mostly uncontrolled studies; the authors say results must be interpreted carefully. PCOS guidelines do not yet favour any one diet.
Important Disclaimer
This directory is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making changes to your medication regimen or starting any new therapy.

This document does not guarantee the legitimacy, quality, or suitability of any business, organization, or practitioner listed within. The inclusion of any listing does not constitute an endorsement, recommendation, or verification of credentials. All organizations listed are independent entities over which the creators of this directory have no control or oversight.

This directory is intended to be used as a starting point and reference for the reader to conduct their own research, exercise their own judgment, and apply their own discretion before engaging with any listed organization or professional. Readers are strongly encouraged to independently verify credentials, read reviews, check licensing, and confirm current pricing and availability directly with each organization before committing to any services.

Costs, availability, contact details, and services may change at any time without notice. Information was accurate to the best of our knowledge at the time of publication.

About Notbroken.io: this directory and the accompanying Breathe, Calm, Sleep, Move, Eat, Track and Build tools were created by Nathan Leary, who runs and updates them. How each tool works, its safety notes, the privacy policy and terms of use are at notbroken.io/about, notbroken.io/privacy and notbroken.io/terms. The tools are general wellness aids, not medical devices, and Track is a personal journal that never gives medication advice.

If you are in crisis: Please contact your local emergency services immediately, or reach out to one of the following helplines:

International: Chapter 02 of this directory lists free helplines by situation and country; elsewhere use Find A Helpline — findahelpline.com
United States: 988 Suicide & Crisis Lifeline (call or text 988) • Crisis Text Line (text HOME to 741741)
United Kingdom: Samaritans — 116 123 (free, 24/7)
Canada: Talk Suicide Canada — 988 (call or text, 24/7)
Australia: Lifeline — 13 11 14 (24/7) • Beyond Blue — 1300 22 4636
New Zealand: Need to Talk? — 1737 (free, 24/7)
Europe: European Emergency Number — 112
India: iCall — 9152987821 • Vandrevala Foundation — 1860 2662 345
Singapore: Samaritans of Singapore — 1-767 (24/7)
Japan: TELL Lifeline — 03-5774-0992

No matches found

Nothing matched . Try broadening your search — remove a filter, use a single keyword, describe what you need in a sentence, or browse by a condition, a place, or a type of support.

Suggest a resource